Regentis Biomaterials Advances 10-Minute GelrinC Hydrogel in $3B Cartilage Repair Market
RGNT•Regentis Biomaterials is advancing GelrinC, a cell-free hydrogel implant for knee cartilage repair offering a 10-minute, single-step procedure that delivers 100% greater pain improvement versus microfracture. With CE Mark approval, its U.S. Phase III trial is over 50% enrolled as it targets a $3 billion market of 470,000 repair cases.
1. GelrinC Hydrogel Implant Overview
GelrinC is a cell-free, off-the-shelf hydrogel designed to simplify knee cartilage repair into a single 10-minute procedure. Clinical data demonstrate approximately 100% greater pain improvement compared with microfracture and MRI-confirmed regeneration of near-native cartilage with durable multi-year outcomes.
2. Market Opportunity
The U.S. knee cartilage repair market is estimated at $3 billion, with roughly 470,000 annual cases and currently no approved off-the-shelf regenerative solutions. GelrinC aims to capture this unmet need by providing a minimally invasive alternative to traditional microfracture and complex cell-based therapies.
3. Regulatory and Clinical Progress
GelrinC has secured CE Mark approval in Europe and is progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. Upcoming catalysts include potential European commercialization, completion of the Phase III study, and preparation for an eventual FDA submission.
